By Josh White
Date: Thursday 26 Sep 2024
(Sharecast News) - AstraZeneca announced on Thursday that 'Tagrisso', or osimertinib, has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, stage three epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease had not progressed after platinum-based chemoradiation therapy...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news